Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

460 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur
Phase 2 CLL & Richter's syndrome #NCT06588478 #2024-515689-15-01
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology
Phase 2 Lung cancer #NCT06868485 #2024-519713-65-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Wayshine Biopharm, Inc.
Phase 2 Lung cancer #NCT06667908
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Janssen
Phase 2 Breast cancer #NCT04680715
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Centre Antoine Lacassagne
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04428554
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Institut Claudius Regaud
Phase 2 Breast cancer #NCT04666961
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRCA 1/2
7 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 2 Lung cancer #NCT05718323
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
ETOP IBCSG Partners Foundation
Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT06475352
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
37 recruiting sites
UNICANCER
Phase 2 Lymphoma #NCT04920617
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
ImmunoVaccine Technologies, Inc.
Phase 1 / Phase 2 Breast cancer Stomach and esophageal cancer #NCT06324357 #2023-509566-38-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim